Humoral Response to mRNA-1273 SARS-CoV-2 Vaccine in Peritoneal Dialysis Patients: Is Boostering After Six Months Adequate?

Frontiers in Medicine

article

Georg Beilhack¹  Rossella Monteforte¹  Florian Frommlet²  Roman Reindl-Schwaighofer¹  Robert Strassl³  Andreas Vychytil¹ 

[1] Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna;Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna;Division of Clinical Virology, Medical University of Vienna

关键词: COVID-19;    peritoneal dialysis;    anti-SARS-CoV-2 antibodies;    booster;    mRNA-1273 vaccine;    spikevax;   

DOI  :  10.3389/fmed.2022.905798

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

In dialysis patients the humoral response to anti-SARS-CoV-2 vaccines is attenuated and rapidly declines over time. However, data on the persistence of the immune response in peritoneal dialysis (PD) patients are scarce, particularly after a third (booster) dose with mRNA-1273 vaccine. In this prospective cohort study, we report anti-SARS-CoV-2 antibody levels in PD patients before and after the third dose of mRNA-1273 vaccine. Six months after the second dose, anti-SARS-CoV-2 antibodies were detected in all patients ( n = 34). However, within this time period antibodies substantially declined in 31 of 34 patients (4.5-fold, median = 192 BAU/mL, p = 1.27 × 10 –9 ) and increased in three patients. In accordance with government regulations, a third dose of mRNA-1273 vaccine (50 μg) was given to 27 PD patients 6 months after the second dose which induced a significant increase of anti-SARS-CoV-2 antibody titers (58.6-fold, median = 19405 BAU/mL, p = 1.24 × 10 –29 ). A mixed model analysis showed that a lower Davies Comorbidity Score and a higher GFR were associated with higher antibody titers ( p = 0.03 and p = 0.02). The most common adverse events after the third dose were pain at the injection site (77.8%) and fatigue (51.9%). No hospitalizations were reported. In conclusion, 6 months after the second dose of mRNA-1273 vaccine, anti-SARS-CoV-2 antibodies substantially decreased in PD patients, whereas a well-tolerated third dose induced a robust humoral response. Our data suggest that the administration of a booster dose within a shorter interval than 6 months should be considered in PD patients in order to maintain high anti-SARS-CoV-2 antibody levels and assure protection from severe COVID-19 disease.

【 授权许可】

CC BY